Neurology-Focused Longboard Pharmaceuticals' Stock Soars Over 200% Today - Here's Why

Longboard Pharmaceuticals Inc LBPH released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs).

In the study, 52 participants were enrolled to evaluate the safety, tolerability, efficacy, and pharmacokinetics of oral bexicaserin (6 mg, 9 mg, and 12 mg) three times daily (TID) versus placebo. 

The median change in countable motor seizure frequency (primary efficacy endpoint) from baseline for the evaluable participants treated with bexicaserin (n=35) was a decrease of 53.3%, compared to a 20.8% decrease for those receiving placebo (n=9). 

Overall, this represents a placebo-adjusted reduction in seizure frequency of 32.5%. 

The median change in countable motor seizure frequency from baseline in the DS, LGS, and DEE Other cohorts decreased by 72.1%, 48.1%, and 61.2%, respectively. 

This represents a placebo-adjusted reduction in seizure frequency of 27.3% and 28.6% in LGS and DEE Other, respectively.

Bexicaserin exhibited favorable safety and tolerability results. Most participants (85.7%) in the bexicaserin treated group (n=35) that started the maintenance period tolerated the highest dose (12 mg). 

100% of the participants who completed the PACIFIC Study elected to enroll in the ongoing 52-week open-label extension study.

Price Action: LBPH shares are up 190.10% at $17.52 on the last check Tuesday.